HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review

被引：38

作者：

de Carvalho, Nathalia Pacifico ^{[1
]}

Pinto Mendicino, Cassia Cristina ^{[1
]}

Fonseca Candido, Raissa Carolina ^{[1
]}

Dutra Alecrim, Denyr Jeferson ^{[2
]}

Menezes de Padua, Cristiane Aparecida ^{[1
]}

机构：

[1] Univ Fed Minas Gerais, Dept Farm Social, Fac Farm, Belo Horizonte, MG, Brazil

[2] Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil

来源：

AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV | 2019年 / 31卷 / 10期

关键词：

Pre-exposure prophylaxis; PrEP; transgender women; HIV prevention; awareness; acceptability; TRANSGENDER WOMEN; ANTIRETROVIRAL PROPHYLAXIS; CLINICAL-TRIALS; BLACK-MEN; SEX; RISK; PREVENTION; ADHERENCE; GENDER; SAFETY;

D O I：

10.1080/09540121.2019.1612014

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Transgender (trans) women are disproportionally burdened by the HIV epidemic due to complex structural, psychosocial and biological factors. HIV pre-exposure prophylaxis (PrEP) is a biomedical prevention approach for people at substantial risk of acquiring HIV. This literature review assessed awareness, willingness to use, and barriers and facilitators for PrEP acceptability among trans women. A search was conducted through five databases and included studies with primary data and disaggregate results for trans women. Of 255 retrieved citations, 17 met the inclusion criteria and were included. Low to moderate knowledge about PrEP was observed among studies. However, willingness to use PrEP was predominantly high. Frequent barriers to PrEP acceptability included concerns about side effects, cost, hormone therapy, adherence, PrEP-related stigma and interaction with healthcare workers. Facilitators included perceived reduction of HIV risk, fear of HIV/AIDS and reduced dependence on partners. Findings suggest elevated interest in PrEP and highlight important barriers and facilitators that should be specifically addressed to optimize PrEP uptake and use among this highly vulnerable population.

引用

页码：1234 / 1240

页数：7

共 52 条

[1]

[Anonymous], 6 IAS C HIV PATH TRE

[2]

[Anonymous], 2017, Ending AIDS: Progress towards the 909090 targets

[3]

[Anonymous], 2012, Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects

[4] Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women [J].

Baeten, J. M. ;

Donnell, D. ;

Ndase, P. ;

Mugo, N. R. ;

Campbell, J. D. ;

Wangisi, J. ;

Tappero, J. W. ;

Bukusi, E. A. ;

Cohen, C. R. ;

Katabira, E. ;

Ronald, A. ;

Tumwesigye, E. ;

Were, E. ;

Fife, K. H. ;

Kiarie, J. ;

Farquhar, C. ;

John-Stewart, G. ;

Kakia, A. ;

Odoyo, J. ;

Mucunguzi, A. ;

Nakku-Joloba, E. ;

Twesigye, R. ;

Ngure, K. ;

Apaka, C. ;

Tamooh, H. ;

Gabona, F. ;

Mujugira, A. ;

Panteleeff, D. ;

Thomas, K. K. ;

Kidoguchi, L. ;

Krows, M. ;

Revall, J. ;

Morrison, S. ;

Haugen, H. ;

Emmanuel-Ogier, M. ;

Ondrejcek, L. ;

Coombs, R. W. ;

Frenkel, L. ;

Hendrix, C. ;

Bumpus, N. N. ;

Bangsberg, D. ;

Haberer, J. E. ;

Stevens, W. S. ;

Lingappa, J. R. ;

Celum, C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (05) :399-410

[5] Worldwide burden of HIV in transgender women: a systematic review and meta-analysis [J].

Baral, Stefan D. ;

Poteat, Tonia ;

Stromdahl, Susanne ;

Wirtz, Andrea L. ;

Guadamuz, Thomas E. ;

Beyrer, Chris .

LANCET INFECTIOUS DISEASES, 2013, 13 (03) :214-222

[6]

Bockting W.O., 1999, SIECUS REPORT, V28, P3

[7] Syndemic Theory and HIV-Related Risk Among Young Transgender Women: The Role of Multiple, Co-Occurring Health Problems and Social Marginalization [J].

Brennan, Julia ;

Kuhns, Lisa M. ;

Johnson, Amy K. ;

Belzer, Marvin ;

Wilson, Erin C. ;

Garofalo, Robert .

AMERICAN JOURNAL OF PUBLIC HEALTH, 2012, 102 (09) :1751-1757

[8] Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial [J].

Choopanya, Kachit ;

Martin, Michael ;

Suntharasamai, Pravan ;

Sangkum, Udomsak ;

Mock, Philip A. ;

Leethochawalit, Manoj ;

Chiamwongpaet, Sithisat ;

Kitisin, Praphan ;

Natrujirote, Pitinan ;

Kittimunkong, Somyot ;

Chuachoowong, Rutt ;

Gvetadze, Roman J. ;

McNicholl, Janet M. ;

Paxton, Lynn A. ;

Curlin, Marcel E. ;

Hendrix, Craig W. ;

Vanichseni, Suphak .

LANCET, 2013, 381 (9883) :2083-2090

[9] Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 [J].

Coleman, E. ;

Bockting, W. ;

Botzer, M. ;

Cohen-Kettenis, P. ;

DeCuypere, G. ;

Feldman, J. ;

Fraser, L. ;

Green, J. ;

Knudson, G. ;

Meyer, W. ;

Monstrey, S. ;

Adler, R. ;

Brown, G. ;

Devor, A. ;

Ehrbar, R. ;

Ettner, R. ;

Eyler, E. ;

Garofalo, R. ;

Karasic, D. ;

Lev, A. ;

Mayer, G. ;

Meyer-Bahlburg, H. ;

Hall, B. ;

Pfaefflin, F. ;

Rachlin, K. ;

Robinson, B. ;

Schechter, L. ;

Tangpricha, V. ;

van Trotsenburg, M. ;

Vitale, A. ;

Winter, S. ;

Whittle, S. ;

Wylie, K. ;

Zucker, K. .

INTERNATIONAL JOURNAL OF TRANSGENDERISM, 2012, 13 (04) :165-232

[10] HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial [J].

Deutsch, Madeline B. ;

Glidden, David V. ;

Sevelius, Jae ;

Keatley, Joanne ;

McMahan, Vanessa ;

Guanira, Juan ;

Kallas, Esper G. ;

Chariyalertsak, Suwat ;

Grant, Robert M. .

LANCET HIV, 2015, 2 (12) :E512-E519

← 1 2 3 4 5 6 →